Related Experiment Video
Updated: Nov 28, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Tissue Factor-Targeted "O2-Evolving" Nanoparticles for Photodynamic Therapy in Malignant Lymphoma
Ziying Li1,2, Yanxue Yin1,2, Weiwei Jin3
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Vascular-targeted PDT (vPDT) has produced promising results in the treatment of many cancers, including drug-resistant ones, but little is known about its efficacy in lymphoma. Unfortunately, the lack of a specific therapeutic target and a hypoxic microenvironment for lymphoma jeopardizes the efficacy of vPDT severely. In this study, we designed a lymphoma tissue factor-targeted "O2-evolving" strategy combining PDT with catalase and HMME-encapsulated, EGFP-EGF1-modified PEG-PLGA nanoparticles (CENPs) to boost PDT efficiency; this combination takes advantage of the low oxygen tension of lymphoma. In our results, CENPs accumulated effectively in the vascular lymphoma in vivo and in vitro, and this accumulation increased further with PDT treatment. Per positron emission tomography imaging, combining CENPs with PDT inhibited lymphoma glucose metabolism significantly. The expression of hypoxia-inducible factor (HIF)-1α in the entrapped catalase groups reduced markedly. These data show that the combined administration of PDT and CENPs can prompt tissue factor-cascade-targeted and self-supply of oxygen and that it has a good therapeutic effect on malignant lymphoma.
Insights
This study introduces a novel oxygen-evolving nanoparticle strategy to enhance photodynamic therapy (PDT) for lymphoma. The combination therapy effectively targets lymphoma vasculature and improves treatment outcomes by increasing oxygen supply.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Oncology
Background:
- Vascular-targeted photodynamic therapy (vPDT) shows promise for cancers but faces challenges in lymphoma due to hypoxia and lack of specific targets.
- Lymphoma's hypoxic microenvironment and undefined therapeutic targets limit vPDT efficacy.
Purpose of the Study:
- To develop an "O2-evolving" nanoparticle strategy targeting lymphoma vasculature to enhance vPDT efficacy.
- To investigate the combined therapeutic effect of vPDT and novel nanoparticles in lymphoma models.
Main Methods:
- Designed catalase and HMME-encapsulated nanoparticles (CENPs) modified with EGFP-EGF1 for lymphoma targeting.
- Evaluated CENP accumulation in lymphoma vasculature in vitro and in vivo.
- Assessed the impact of combined vPDT and CENPs on lymphoma glucose metabolism and hypoxia-inducible factor (HIF)-1α expression using PET imaging.
Main Results:
- CENPs demonstrated effective accumulation in lymphoma vasculature, which was enhanced by PDT treatment.
- Combined vPDT and CENPs significantly inhibited lymphoma glucose metabolism.
- Hypoxia-inducible factor (HIF)-1α expression was markedly reduced in groups receiving entrapped catalase.
Conclusions:
- The developed "O2-evolving" nanoparticle strategy effectively targets lymphoma vasculature via tissue factor.
- Combined vPDT and CENPs promote self-oxygen supply, overcoming hypoxia and demonstrating significant therapeutic effects against malignant lymphoma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...